Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.

Cancer Commun (Lond) · 2025 · PMC12629865 · PMID 40974551

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median tumor‐to‐kidney dose ratio showed a modest improvement with SG co‐infusion, rising from 11.6 to 13.0, although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.